News
Academy
Publications
All PublicationsE-Books
Media
Editorial PodcastsEditorial VideosPeer ExchangePractice AcademySponsored PodcastsSponsored Videos
More
Conferences
Conference CoverageConference Listing
Columns
All ColumnsA Closing ThoughtClinical Trial InsightsView from BrusselsView from Washington
Resources
AdvertiseBlogsEventsFront & CenterPartner PerspectivesWhite Papers
Webcasts

Subscribe

  • News
  • Academy
  • Publications
    • Media
      • Conferences
        • Columns
          • Resources
            • Webcasts
            • Subscribe
            Spotlight -
            Conference Coverage|
            Peer Exchange|
            DE&I|
            Editorial Videos
            Advertisement
            |Articles|October 28, 2016

            ACT Article Submission

            Advertisement
            External Link - ACT_Author_Guidelines.pdf

            Newsletter

            Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.

            Subscribe Now!
            Advertisement

            Related Articles

            • Investigational PD-L1 x VEGF-A Bispecific Antibody Demonstrates Strong Overall Response Rate in Phase II Small Cell Lung Cancer Trial
              Investigational PD-L1 x VEGF-A Bispecific Antibody Demonstrates Strong Overall Response Rate in Phase II Small Cell Lung Cancer Trial

              September 10th 2025

            • Ensuring Digital Trial Platforms Work for Underserved Communities
              Ensuring Digital Trial Platforms Work for Underserved Communities

              September 10th 2025

            • eClinical Technology: Misconceptions, Challenges, and Opportunities
              eClinical Technology: Misconceptions, Challenges, and Opportunities

              September 9th 2025

            • © iDoPixBox - © iDoPixBox - stock.adobe.com
              Phase III EMPOWER-Lung 3 Trial Confirms Five-Year Survival Benefit With Libtayo Plus Chemotherapy in NSCLC

              September 9th 2025

            • Investigational OX40-Targetting T-Cell Therapy Shows Durable Efficacy Treating Atopic Dermatitis in Phase III Trial
              Investigational OX40-Targetting T-Cell Therapy Shows Durable Efficacy Treating Atopic Dermatitis in Phase III Trial

              September 9th 2025

            • AstraZeneca’s Tagrisso Shows Landmark Overall Survival Benefit in Non-Small Cell Lung Cancer
              AstraZeneca’s Tagrisso Shows Landmark Overall Survival Benefit in Non-Small Cell Lung Cancer

              September 9th 2025

            Advertisement
            Advertisement

            Trending on Applied Clinical Trials Online

            1

            AstraZeneca’s Tagrisso Shows Landmark Overall Survival Benefit in Non-Small Cell Lung Cancer

            2

            Investigational OX40-Targetting T-Cell Therapy Shows Durable Efficacy Treating Atopic Dermatitis in Phase III Trial

            3

            Summit Therapeutics’ Bispecific Antibody Shows Positive Survival Trend in Non-Small Cell Lung Cancer

            4

            Pfizer, BioNTech’s Comirnaty Shows Strong Immune Response in Phase III Trial for COVID-19

            5

            Phase III EMPOWER-Lung 3 Trial Confirms Five-Year Survival Benefit With Libtayo Plus Chemotherapy in NSCLC

            • About
            • Advertise
            • Contact Us
            • Editorial Contacts
            • Do Not Sell My Personal Information
            • Privacy Policy
            • Terms and Conditions
            Contact Info

            259 Prospect Plains Rd, Bldg H
            Monroe, NJ 08831

            609-716-7777

            • Applied Clinical Trials
            • BioPharm International
            • Cannabis Science and Technology
            • Chromatography Online
            • Nutritional Outlook
            • Pharmaceutical Commerce
            • Pharmaceutical Executive
            • Pharm Tech
            • Spectroscopy Online
            • Turbo Machinery Magazine
            IS1
            Brand Logo

            © 2025 MJH Life Sciences®

            All rights reserved.

            Home
            About Us
            News
            Contact Us